Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 19/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290088 | 0.89 | GABRA5 (0.80) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL2684854 | 0.86 | GABRA5 (1.00) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL5960871 | 0.84 | GABRA5 (0.72) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL4407568 | 0.84 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL5960036 | 0.83 | GABRA5 (0.71) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL2686994 | 0.83 | GABRA5 (0.71) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL4404830 | 0.83 | GABRA5 (1.00) | GABRA5GABRG2GABRB3KCNH2DGAT2 | |
| SCHEMBL2682741 | 0.82 | GABRA5 (0.70) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL2682578 | 0.82 | GABRA5 (0.70) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL16086927 | 0.81 | GABRA5 (0.68) | GABRA5GABRG2GABRB3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885GABRG2 21/4885GABRB3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.